Healthcare utilization and costs for patients initiating Dabigatran or Warfarin

BACKGROUND: Novel oral anticoagulants (NOAC) such as dabigatran, when compared to warfarin, have been shown to potentially reduce the risk of stroke in patients with non-valvular atrial fibrillation (NVAF) together with lower healthcare resource utilization (HCRU) and similar total costs. This study...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Health Qual Life Outcomes
Main Authors: Reynolds, Shannon L., Ghate, Sameer R., Sheer, Richard, Gandhi, Pranav K., Moretz, Chad, Wang, Cheng, Sander, Stephen, Costantino, Mary E., Annavarapu, Srinivas, Andrews, George
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2017
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5480105/
https://ncbi.nlm.nih.gov/pubmed/28637460
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12955-017-0705-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados